Pemigatinib 13.5 mg Tablet
Product Overview
Pemigatinib 13.5 mg Tablet is a targeted cancer therapy used for the treatment of FGFR2 fusion–positive cholangiocarcinoma in adult patients. Pemigatinib is a selective fibroblast growth factor receptor (FGFR) inhibitor that helps slow cancer growth by blocking abnormal FGFR signaling pathways.
This medicine is prescribed for patients with advanced or metastatic bile duct cancer who have previously received systemic therapy. FGFR2 genetic testing is required before starting treatment with Pemigatinib 13.5 mg Tablet.
Uses / Indications of Pemigatinib 13.5 mg Tablet
Pemigatinib 13.5 mg Tablet is used for:
-
FGFR2 fusion–positive cholangiocarcinoma
-
Advanced or metastatic bile duct cancer
-
Adult patients who have received prior systemic cancer therapy
How Pemigatinib 13.5 mg Tablet Works
Pemigatinib 13.5 mg Tablet works by:
-
Inhibiting FGFR1, FGFR2, and FGFR3 enzymes
-
Blocking abnormal FGFR-driven cancer cell signaling
-
Reducing tumor cell growth and survival
-
Slowing disease progression in FGFR2-positive cholangiocarcinoma
Dosage & Administration
-
Dosage of Pemigatinib 13.5 mg Tablet is determined by a qualified oncologist
-
Taken orally, with or without food
-
Follow the prescribed treatment cycle strictly
⚠️ Do not change the dose or stop taking Pemigatinib without medical advice.
Possible Side Effects of Pemigatinib 13.5 mg Tablet
Common side effects may include:
-
Fatigue
-
Diarrhea
-
Nausea
-
Dry mouth
-
Changes in phosphate levels
-
Nail or skin changes
Side effects may vary depending on the patient’s condition and response to treatment.
Warnings & Precautions
-
Prescription-only medicine
-
FGFR2 mutation testing is mandatory before treatment
-
Not recommended during pregnancy or breastfeeding
-
Regular laboratory and clinical monitoring may be required
-
Use only under specialist supervision
Storage Instructions
-
Store Pemigatinib 13.5 mg Tablet below 30°C
-
Protect from moisture and direct light
-
Keep out of reach of children
Frequently Asked Questions (FAQ)
What is Pemigatinib 13.5 mg Tablet used for?
Pemigatinib 13.5 mg Tablet is used to treat FGFR2-positive cholangiocarcinoma in adult patients.
Is Pemigatinib chemotherapy?
No. Pemigatinib is a targeted therapy, not traditional chemotherapy.
Is genetic testing required before using Pemigatinib?
Yes. FGFR2 fusion testing is required before starting Pemigatinib 13.5 mg Tablet.
Can Pemigatinib 13.5 mg Tablet be taken daily?
Yes, but only according to the dosing schedule prescribed by an oncologist.
Is Pemigatinib safe?
Pemigatinib is approved for use under specialist supervision and requires regular monitoring during treatment.
Medical Disclaimer
Pemigatinib 13.5 mg Tablet is a prescription-only medicine. Treatment should be initiated and supervised by a qualified oncologist. This information is for educational purposes only and does not replace professional medical advice.
